The story of JAK3 selective inhibitors started after the development of Tofacitinib – a pan-JAK inhibitor that was the first FDA-approved JAK inhibitor for the treatment of RA (rheumatoid arthritis). This evidence concerns the gene JAK3 and rheumatoid arthritis.